Top 3 Health Care Stocks That May Crash This Quarter
Top 3 Health Care Stocks That May Crash This Quarter
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年7月3日,医疗保健板块的三只股票可能对那些将动量视为其交易决策关键标准的投资者发出真正警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一种动量指标,它将股票在股价上升的日子里的强度与在股价下跌的日子里的强度进行比较。与股票价格的走势相比,它可以让交易员更好地了解股票在短期内的表现。当RSI高于70时,资产通常被认为是超买的,据Benzinga Pro称。
Here's the latest list of major overbought players in this sector.
以下是行业中超买的主要股票列表。
Harrow Inc (NASDAQ:HROW)
Harrow股份有限公司(NASDAQ:harrow)
- On June 21, Craig-Hallum analyst Chase Knickerbocker maintained Harrow with a Buy and raised the price target from $26 to $30. The company's stock gained around 22% over the past month and has a 52-week high of $22.63.
- RSI Value: 75.75
- HROW Price Action: Shares of Harrow fell 1% to close at $20.85 on Tuesday.
- 6月21日,Craig-Hallum分析师Chase Knickerbocker建议买入Harrow股份有限公司,并将价格目标从26美元上调至30美元。该公司股票过去一个月上涨了约22%,52周最高价为22.63美元。
- RSI指标: 75.75
- Harrow的股价走势: Harrow的股价在周二下跌1%,收于20.85美元。
Longboard Pharmaceuticals Inc (NASDAQ:LBPH)
长板药业股份有限公司(NASDAQ:LBPH)
- On July 1, Longboard Pharmaceuticals said the FDA granted breakthrough therapy designation for bexicaserin. The company's stock gained around 47% over the past five days and has a 52-week high of $33.74.
- RSI Value: 84.20
- LBPH Price Action: Shares of Longboard Pharmaceuticals closed at $30.74 on Tuesday.
- 7月1日,长板药业表示,美国食品和药物管理局(FDA)授予其bexicaserin突破性疗法指定。公司股票过去五天上涨约47%,52周最高价为33.74美元。
- RSI指标: 84.20
- LBPH的股价走势: 长板药业的股票周二收盘价为30.74美元。
Eli Lilly And Co (NYSE:LLY)
Eli Lilly And Co(NYSE: LLY)
- On July 2, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company's Alzheimer's treatment, "Kisunla." The company's stock gained around 10% over the past month and has a 52-week high of $916.83.
- RSI Value: 74.03
- LLY Price Action: Shares of Eli Lilly closed at $906.71 on Tuesday.
- 7月2日,美国食品药品监督管理局(FDA)已批准礼来公司(Eli Lilly and Company)的阿尔茨海默病治疗药物“基舒利”。“基舒利”的股价上涨约10%,52周最高价为916.83美元。
- RSI指标: 74.03
- LLY的股价走势: 艾默生的股票周二收盘价为906.71美元。
Read More: Tesla To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Wednesday
更多阅读:特斯拉将上涨约30%?以下是周三10个顶尖分析师的预测